Technique identifies chemotherapy-resistant cells within acute myeloid leukemia tumors

September 6, 2016

Although chemotherapy can sometimes cure acute myeloid leukemia and other hematologic cancers, many patients experience relapses when their tumors become resistant to available chemotherapies. This resistance may be caused by the survival and proliferation of chemotherapy-resistant cells that were already present in the tumor prior to treatment. Studying the characteristics of these cells could help researchers understand and develop better approaches to target chemotherapy-resistant cancers.

This month in the JCI, Anthony Letai and colleagues at the Dana-Farber Cancer Institute developed an assay to determine how variability within a population of can predict responses to chemotherapy in acute myeloid leukemia patients.

The assay, which was performed on , measured each cell's sensitivity to mitochondrial apoptosis, a type of cell death that is induced by many existing chemotherapies.

They determined that the least sensitive cells in a tumor could predict how successfully a patient responded to chemotherapy. Developing the ability to identify chemotherapy-resistant tumors and tumor cells prior to treatment may lead to clinical insights that improve therapeutic outcomes in and other cancers.

Explore further: Study provides new clues to leukemia resurgence after chemotherapy

More information: Patrick D. Bhola et al, Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia, Journal of Clinical Investigation (2016). DOI: 10.1172/JCI82908

Related Stories

Study provides new clues to leukemia resurgence after chemotherapy

June 2, 2016
For the first time, researchers have discovered that some leukemia cells harvest energy resources from normal cells during chemotherapy, helping the cancer cells not only to survive, but actually thrive, after treatment.

Immune cells help reverse chemotherapy resistance in ovarian cancer

May 20, 2016
Inside each ovarian tumor, there are good cells and bad cells. A new paper explains their roles:

Tumor microenvironment acts as a mechanism of resistance to chemotherapy

September 6, 2016
Researchers at Bellvitge Biomedical Research Institute (IDIBELL) have published a study in Oncotarget that highlights the importance of the tumor environment as a source of resistance to treatment in colorectal cancer, the ...

Identification of a novel tyrosine kinase inhibitor for acute myeloid leukemia

March 17, 2016
Acute myeloid leukemia (AML) is a cancer of myeloid stem cells that develops in both adult and pediatric populations. Mutations that cause hyperactivation of the FMS-like tyrosine kinase 3 (FLT3) are commonly found in AML, ...

As leukemia evolves, stem cells hold keys to newer therapies

August 30, 2016
A recent study by University of Rochester Medical Center researchers proves why leukemia is so difficult to treat and suggests that the current approach to drug development should be adjusted to target a broader range of ...

Innate immune landscape in glioblastoma patient tumors

February 25, 2016
Glioblastoma is an extremely aggressive brain tumor with limited treatment options. Recent progress in using immunotherapy-based treatment options in other tumor types has spurred interest in developing approaches that might ...

Recommended for you

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

Using artificial intelligence to improve early breast cancer detection

October 17, 2017
Every year 40,000 women die from breast cancer in the U.S. alone. When cancers are found early, they can often be cured. Mammograms are the best test available, but they're still imperfect and often result in false positive ...

New assay may boost targeted treatment of non-Hodgkin lymphoma

October 17, 2017
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment ...

Biology of childhood brain tumor subtypes offers clues to precision treatments

October 17, 2017
Researchers investigating pediatric low-grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.